Improving the 510(k) FDA Process for Cardiac Troponin Assays: In Search of Common Ground
Open Access
- 1 October 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (10) , 1273-1275
Abstract
We met recently with the leadership of the Food and Drug Administration's (FDA's)6 Division of Chemistry and Toxicology Devices to discuss concerns about the heKeywords
Funding Information
- Roche
- Abbott
- Siemens
- Abbott
- Alere
- Siemens
- Roche
This publication has 9 references indexed in Scilit:
- Troponin Elevations Only Detected With a High‐sensitivity Assay: Clinical Correlations and Prognostic SignificanceAcademic Emergency Medicine, 2014
- Validation of High-Sensitivity Troponin I in a 2-Hour Diagnostic Strategy to Assess 30-Day Outcomes in Emergency Department Patients With Possible Acute Coronary SyndromeJACC, 2013
- Preparing the United States for High-Sensitivity Cardiac Troponin AssaysJACC, 2013
- Influence of Population Selection on the 99th Percentile Reference Value for Cardiac Troponin AssaysClinical Chemistry, 2012
- Analytical Characteristics of High-Sensitivity Cardiac Troponin AssaysClinical Chemistry, 2012
- Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General PopulationJAMA, 2010
- Recommendations for the use of cardiac troponin measurement in acute cardiac careEuropean Heart Journal, 2010
- The Association Between Emergency Department Crowding and Adverse Cardiovascular Outcomes in Patients with Chest PainAcademic Emergency Medicine, 2009
- Standardized reporting guidelines for studies evaluating risk stratification of emergency department patients with potential acute coronary syndromesAnnals of Emergency Medicine, 2004